Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Teclistamab · Tecvayli

Bispecific antibody · Immune activation, directed at CD3 (CD3E) and B-cell maturation antigen (BCMA) (TNFRSF17) · developed by Janssen Biotech

Approved FDA, Oct 2022
JNJ Developer
1 Registered trials

What is Teclistamab?

Teclistamab is a bispecific T-cell engaging antibody that binds CD3 on T-cells and B-cell maturation antigen (BCMA) on multiple myeloma cells and some healthy B-lineage cells. By cross-linking T-cells with tumor cells, it activates T-cells, triggers proinflammatory cytokine release and lyses myeloma cells. It is studied in multiple myeloma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Tecvayli, JNJ-64007957
Drug type
Bispecific antibody
Targets
CD3 (CD3E), B-cell maturation antigen (BCMA) (TNFRSF17)
Mechanism
Immune activation, directed at CD3 (CD3E) and B-cell maturation antigen (BCMA) (TNFRSF17)
Pathways
T-cell activation, proinflammatory cytokine release, cytotoxic T-lymphocyte response
Therapy area
Oncology
Developer
Janssen Biotech (JNJ)
FDA status
Approved as Tecvayli (October 25, 2022), BLA761291 · FDA label
UNII
54534MX6Z9

✅ FDA-approved uses

From the indications section of the FDA label (version of Mar 10, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07030517 Phase 4 Multiple Myeloma Active not recruiting JNJ

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple Myeloma

Other drugs acting on CD3E / TNFRSF17

More from Janssen Biotech

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the JNJ page.

Follow JNJ, the company behind Teclistamab

See JNJ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

JNJ catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.